Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation

A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers led by the Perelman School of Medicine and the Basser Center for BRCA at the University of Pennsylvania reported their findings this week in JCO Precision Oncology.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news